Corporate News

Conditional Subscription - Update re HMRC Advance Assurance

17 February 2021

Further to the announcements of 29 January 2021, MyHealthChecked plc (AIM: MHC),   the consumer home-testing healthcare company, announces it has now received Advance Assurance from HM Revenue and Customs that the ordinary shares to be issued are eligible for relief under the Enterprise Investment Scheme. This fulfils one of the conditions for the allotment of the 28,571,428 Conditional Subscription Shares detailed in the 29 January 2021 announcements.

The allotment of the Conditional Subscription Shares remains conditional, inter alia, upon approval by Shareholders of the Resolutions to be proposed at the General Meeting scheduled for 11.00 a.m. on 18 February 2021.

Application will be made for admission of the Conditional Subscription Shares to trading on AIM; it is expected that the Conditional Subscription Shares will be admitted to trading on AIM ("Admission") at 8.00 a.m. on or around 22 February 2021.

Total Voting Rights

Following Admission, the Company will have a total of 725,246,036 Ordinary Shares in issue with each Ordinary Share carrying the right of one vote. The above figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement released on 29 January 2021 unless the context requires otherwise.


For further information please contact:

MyHealthChecked plc

www.myhealthcheckedp lc .com

Penny McCormick , Chief Executive Officer

via Walbrook PR

Maddy Kennedy, Chief Financial Officer


SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin


Oberon Investments  (Broker)

Tel: +44 (0)203 179 5344

Mike Seabrook

[email protected]


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44(0)7980 541 893